Literature DB >> 29888203

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2018        PMID： 29888203      PMCID： PMC5985409          DOI： 10.1159/000488542

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  20 in total

1.  Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-12-15       Impact factor: 11.740

2.  Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Authors:  Jordi Bruix; Won-Young Tak; Antonio Gasbarrini; Armando Santoro; Massimo Colombo; Ho-Yeong Lim; Vincenzo Mazzaferro; Reiner Wiest; María Reig; Andrea Wagner; Luigi Bolondi
Journal:  Eur J Cancer       Date:  2013-06-25       Impact factor: 9.162

3.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

4.  S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Masatoshi Kudo; Michihisa Moriguchi; Kazushi Numata; Hisashi Hidaka; Hironori Tanaka; Masafumi Ikeda; Seiji Kawazoe; Shinichi Ohkawa; Yozo Sato; Shuichi Kaneko; Junji Furuse; Madoka Takeuchi; Xuemin Fang; Yoshito Date; Masahiro Takeuchi; Takuji Okusaka
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-04-06

5.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

Review 6.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

7.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Authors:  Andrew X Zhu; Masatoshi Kudo; Eric Assenat; Stéphane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T P Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B Sellami; Li-Tzong Chen
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

8.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

Review 9.  Regorafenib for cancer.

Authors:  Dirk Strumberg; Beate Schultheis
Journal:  Expert Opin Investig Drugs       Date:  2012-06       Impact factor: 6.206

10.  Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonio Daniele Pinna; Benjamin Djulbegovic; Federico Mazzotti; Luigi Bolondi
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740
View more
  7 in total

Review 1.  Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.

Authors:  Emma D Deeks
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

Review 2.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

3.  Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.

Authors:  Fabian Finkelmeier; Bernhard Scheiner; Catherine Leyh; Jan Best; Thorben Wilhelm Fründt; Carolin Czauderna; Alica Beutel; Dominik Bettinger; Johannes Weiß; Tobias Meischl; Fabian Kütting; Dirk-Thomas Waldschmidt; Pompilia Radu; Michael Schultheiß; Kai-Henrik Peiffer; Thomas J Ettrich; Arndt Weinmann; Henning Wege; Marino Venerito; Jean-Francois Dufour; Christian M Lange; Matthias Pinter; Oliver Waidmann
Journal:  Liver Cancer       Date:  2021-06-01       Impact factor: 11.740

4.  LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway.

Authors:  Qian Shen; Shenhua Jiang; Mingyun Wu; Lei Zhang; Xue Su; Ding Zhao
Journal:  Cancer Manag Res       Date:  2020-07-29       Impact factor: 3.989

5.  Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Amir Shlomai; Moshe Leshno; Daniel A Goldstein
Journal:  Therap Adv Gastroenterol       Date:  2019-09-23       Impact factor: 4.409

Review 6.  Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2018-10-30       Impact factor: 6.639

7.  The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.

Authors:  Hiroaki Kanzaki; Tetsuhiro Chiba; Junjie Ao; Keisuke Koroki; Kengo Kanayama; Susumu Maruta; Takahiro Maeda; Yuko Kusakabe; Kazufumi Kobayashi; Naoya Kanogawa; Soichiro Kiyono; Masato Nakamura; Takayuki Kondo; Tomoko Saito; Ryo Nakagawa; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Ryosuke Muroyama; Shingo Nakamoto; Shin Yasui; Akinobu Tawada; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Naoya Mimura; Jun Kato; Yoh Zen; Masayuki Ohtsuka; Atsushi Iwama; Naoya Kato
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.